Everything tagged "healthcare" across research, earnings, and macro.
70 articles
Sonida Senior Living, Inc. (SNDA) slips 3.3% after reporting earnings misses, as investors react to weaker-than-expected results and pressure on the stock.
Zoetis remains a high-quality animal health leader, but 2026 guidance cuts and softer U.S. companion-animal demand temper the near-term setup. The stock looks like a disciplined Buy with a fair value of $132.
Insulet beat on EPS and revenue, lifted full-year guidance, and still saw PODD drop sharply. This deep-dive looks beyond the headline beat to examine Omnipod growth, margin expansion, guidance nuance, and why investors focused on valuation and reaction rather than the strong quarter.
Cencora, Inc. (COR) slumps after missing on EPS and revenue, but the full story goes beyond the headline. This deep-dive unpacks U.S. Healthcare Solutions pressure, international strength, margin shifts, and why raised EPS guidance couldn’t offset a revenue reset.
Medline is growing at scale with strong customer retention and a deep med-surg distribution network, but margin pressure and a rich valuation keep the stock from looking cheap.
Insulet is compounding revenue, margins, and free cash flow while expanding Omnipod’s reach in type 1 and type 2 diabetes. The stock still trades at a premium, but the growth runway and product leadership remain compelling.
Cencora is using specialty expansion and GLP-1 volume to grow earnings faster than revenue. The stock looks constructive for medium-term investors, with solid guidance and a reasonable forward valuation.
Cencora, Inc. (COR) slumps 17.4% after reporting earnings misses, as investors react to weaker-than-expected results and pressure on the stock.
Insulet Corporation (PODD) drops 6.3% even after earnings beats, as investors react to the latest quarterly results and outlook.
Revvity, Inc. (RVTY) rises after a clean Q1 earnings beat, but the real story is in the details: stronger-than-expected margins, steady organic growth, and a guidance reset tied to a strategic China exit rather than core business weakness. Here’s what the numbers and outlook really mean.
Fresenius Medical Care posted a sharp 2025 profitability step-up, but 2026 is a transition year as temporary benefits roll off and rollout costs rise. The stock looks like a measured Buy for investors willing to wait for execution to stick.
Revvity is a balanced life sciences and diagnostics operator with improving earnings, solid cash flow, and a growing software mix. The stock looks more like a recovery rerating than a breakout, but valuation is reasonable if forward EPS delivers.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator